has granted Fast Track designation for DYNE-101 for the treatment of myotonic dystrophy type 1 (DM1). DYNE-101 is currently being evaluated in the ongoing Phase 1/2 ACHIEVE global clinical trial.

They help doctors identify diseases that affect the nerves and muscles as well as the extent of any damage. This test is used to diagnose myotonic muscular dystrophy, which causes muscles to stay ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat ...

As they get older they may need to use a cane or wheelchair to get around. The symptoms of myotonic dystrophy may be obvious from birth or they can develop later -- during the teenage or adult years.

Cardiac hypertrophy is the abnormal enlargement, or thickening, of the heart muscle, resulting from increases in cardiomyocyte size and changes in other heart muscle components, such as ...